Listen
OLUMIANT (baricitinib), anti-JAK 1 and 2
RHEUMATOLOGY - New medicinal product
Opinions on drugs -
Posted on
Oct 04 2017
Reason for request
Inclusion
No clinical benefit demonstrated in the treatment of rheumatoid polyarthritis after failure of one or more disease-modifying treatments
- OLUMIANT has marketing authorisation in the treatment of rheumatoid polyarthritis (RP) after failure of one or more disease-modifying treatments.
- It is a second-line treatment after failure of conventional disease-modifying treatments such as methotrexate (MTX) or a third-line treatment (failure of biotherapy) or beyond (failure of multiple conventional disease-modifying and/or biological treatments).
- Its superiority has been demonstrated in combination with MTX compared with adalimumab in combination with MTX in second-line (MTX failure). OLUMIANT has not been compared to available third-line alternatives (in particular tocilizumab, abatacept, rituximab).
- There are concerns in terms of long-term safety, in particular in relation to risks of infection and cardiovascular and carcinogenic risks.
Clinical Benefit
| Substantial |
- |
Clinical Added Value
| no clinical added value |
- |
Therapeutic use
- |
English version
Contact Us
Évaluation des médicaments
